Last updated on November 2015

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients


Brief description of study

This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.

Clinical Study Identifier: NCT02614846

Contact Investigators or Research Sites near you

Start Over

Yu Hu, Ph.D

Union Hospital Tongji Medical College Huazhong University of Science and technology
Wuhan, China
  Connect »